Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study - Wikidata - awgldk - TriplyDB

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

http://www.wikidata.org/entity/Q33438428

about

Development of venetoclax for therapy of lymphoid malignancies.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Venetoclax for the treatment of patients with chronic lymphocytic leukemia.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Venetoclax and obinutuzumab in chronic lymphocytic leukemia.Recent therapeutic advances in chronic lymphocytic leukemia.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.The BCL-2 arbiters of apoptosis and their growing role as cancer targets.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Venetoclax for the treatment of chronic lymphocytic leukemia.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.[Lymphoma in rheumatic diseases].Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?BCL-2 as therapeutic target for hematological malignancies.Targeting BCL-2 regulated apoptosis in cancer.Updates from the 2017 American Society of Hematology annual meeting: practice-changing studies in untreated chronic lymphocytic leukemia.Critical molecular pathways in CLL therapy.Renal involvement in chronic lymphocytic leukemia Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?

P2860

Q37702281-5B35F35E-B2F2-4312-A212-AC7A4FAAF8DB Q38646074-72E80CCC-ADA8-40DF-9D3E-B10F4B315E7B Q38685358-8464D7F3-C14C-49AA-B9F8-D29E91708AAC Q38766548-8B4A364E-8CD5-4BAD-9FA6-B10ECFD48F83 Q38818283-F2E76E4F-B499-4FD4-BC8D-9AE8786A895A Q39267135-2E2EB749-0F4D-472D-84C3-9082B8916EB1 Q42348732-79FB23F3-2469-4255-9B22-5B89DA3F129B Q46318389-B50F3BAE-A65B-410B-AB7E-575E112F930C Q46370948-683355F9-FC44-4F62-B3C8-68F3250723E6 Q47166330-618AA864-A8E0-4CC7-99CB-0BC07386DBBA Q47567993-3790B136-35ED-4357-8DE8-63F3E9A069D0 Q47610956-72845EFC-60C3-4B28-B4E2-E4E081B39D37 Q47875923-726110BE-BE30-40A9-A870-9AD6CEAFE02C Q47932240-D0910142-CA37-48F5-83CA-DF81B6A5C3CF Q48146110-CA834677-AC19-4FF6-843B-E8B6CF72CAC9 Q50054062-A8604272-F162-45DF-8EC3-CB339B3855BD Q50057583-65BBF1B6-193D-453E-8776-8FE04BD7A33A Q50072188-08B9087C-7E3D-4B01-800F-9137F64A2646 Q50074012-F87BB415-101D-462B-951C-B14B6F5841E0 Q51014811-74189DE9-2C4B-4F7D-9F79-6D7C70F23806 Q51842580-26B9A813-1534-4445-9205-6D2B1957C03D Q52661839-305AD0CB-8073-4C2F-B251-CC27253480C9 Q53377800-5050F5EC-F6D8-49E7-8E56-251DF001537B Q53684488-C9C63213-519D-4992-872D-FBDD698DAB13 Q53819035-CF57E042-81E0-45B5-A442-DDAE8F622572 Q55069042-77D25CE0-9390-4156-B449-DB52369C72B0 Q55447785-1F9E6CBE-747E-45F6-B343-4E783B9629BA Q57053852-36B3CD95-CB96-47D4-B852-BBF27F2817CC Q58580676-606A1D86-3DE9-4350-A8E2-845C61B56EE5

P2860

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

http://www.wikidata.org/entity/Q33438428

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@ast

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@en

type

label

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@ast

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@en

prefLabel

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@ast

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@en

P1433

Q33438428-16585379-057B-4CAD-B575-DA54B8577C21

P1476

Q33438428-F1065897-9391-4144-8298-772AE7FF72C6

P2093

Q33438428-12C2482D-7F90-4AFE-9577-A86D5C5BC676

Q33438428-223DFA81-CB3B-486C-9393-00AC3343F362

Q33438428-2FA1FACC-43E0-471C-A278-33ECF78DC199

Q33438428-33622B86-8D31-46D2-B53E-F4538A6170E2

Q33438428-582467CA-BA41-435D-BDF7-8F20BF1A45FF

Q33438428-5FF54A7D-E737-4CEF-B22F-883B52A209E6

Q33438428-6477F4F4-79C0-4AC1-A054-C3DFA5B615B4

Q33438428-6DB996C2-FC6A-44BE-86C3-3CC3950724D8

Q33438428-6E884168-86AE-4208-BEF2-9B4851EC6629

Q33438428-7EBF1879-946B-4F2A-9C50-EA7DCB5D7879

P2860

Q33438428-00F48EBD-FAEA-4057-93AD-E3519A7B1964

Q33438428-05E3E3F9-25E0-435B-9220-0E1F01D8F31A

Q33438428-160BD745-72EB-4138-BBE6-1B9F15F84AEC

Q33438428-1E9940C8-B2F2-4642-AA40-EF5720166FC9

Q33438428-1F71CB08-3D5A-45C0-8610-0827A2C33DF1

Q33438428-237C9AC7-AE65-48E9-A8A0-A09220AAED85

Q33438428-2F67DFA1-5455-4BC8-A452-A269DEEAB2B1

Q33438428-30129BB6-F343-47C1-897A-4B8B411CC388

Q33438428-38E9A326-DBA6-403F-9FA2-D2B99EF46CA0

Q33438428-3DDC02E1-0E1E-4C11-81C0-945F1986FF02

P304

Q33438428-0520F784-9DF9-4026-9671-609B4D7C6592

P31

Q33438428-AD577514-5CEC-451F-A340-FA6D4A56B590

P356

Q33438428-2882206F-852B-480A-AFF8-EA7823BA6DBE

P433

Q33438428-72492F52-96F2-4D73-B0FE-6D0866C2769D

P478

Q33438428-87EBCB4D-BBDA-4F4E-B0AE-6FFD2BF04472

P50

Q33438428-458248FE-25F8-4DED-A420-BBA71E912EB1

Q33438428-5096BFD0-FE4E-4B62-9108-ED4DA2D111E3

Q33438428-6AF0B651-E22D-4989-8F85-FA4F2FB9B7EC

Q33438428-7DEDC697-2404-487F-85A3-8E3FB1D7A406

P577

Q33438428-C4E4F415-0CEC-4140-B126-159C7A31B5D0

P698

Q33438428-6E32E124-744D-4E71-92D6-46C8933CF1FE

P921

Q33438428-D94B69D3-57A4-4D89-ABBE-E48C3CFD96E7

Q33438428-E95E339D-9119-471B-B141-00DBC23FA28B

P932

Q33438428-C7443818-C87C-45B5-9DEE-CF68C94FCF04

P356

S1470-2045(17)30012-8

P1433

The Lancet Oncology

P1476

Venetoclax plus rituximab in r ...... ic leukaemia: a phase 1b study

@en

P2093

Anne W Beaven

http://www.w3.org/2001/XMLSchema#string

Betty Prine

http://www.w3.org/2001/XMLSchema#string

Danielle M Brander

http://www.w3.org/2001/XMLSchema#string

Elisa Cerri

http://www.w3.org/2001/XMLSchema#string

Gary B Gordon

http://www.w3.org/2001/XMLSchema#string

Jacqueline Barrientos

http://www.w3.org/2001/XMLSchema#string

John F Seymour

http://www.w3.org/2001/XMLSchema#string

L Leanne Lash

http://www.w3.org/2001/XMLSchema#string

Maria Verdugo

http://www.w3.org/2001/XMLSchema#string

Matthew S Davids

http://www.w3.org/2001/XMLSchema#string

P2860

The tumor lysis syndrome

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The Bcl-2 apoptotic switch in cancer development and therapy

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

The BCL-2 protein family: opposing activities that mediate cell death

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

P304

230-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(17)30012-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Andrew W Roberts

Constantine S. Tam

Suresh K Agarwal

P577

2017-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28089635

http://www.w3.org/2001/XMLSchema#string

P921

P932

5316338

http://www.w3.org/2001/XMLSchema#string